Company Analysis Enanta Pharmaceuticals, Inc.
1. Summary
Advantages
- Price (10.94 $) is less than fair price (11.59 $)
- The stock's return over the last year (14.05%) is higher than the sector average (-48.76%).
Disadvantages
- Dividends (0%) are below the sector average (0.5526%).
- Current debt level 5.74% has increased over 5 years from 0.0707%.
- The company's current efficiency (ROE=-61.74%) is lower than the sector average (ROE=9.61%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Enanta Pharmaceuticals, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -4.4% | 3.1% | 0.4% |
| 90 days | -31.6% | -35.4% | 13.7% |
| 1 year | 14% | -48.8% | 36.2% |
ENTA vs Sector: Enanta Pharmaceuticals, Inc. has outperformed the "Healthcare" sector by 62.81% over the past year.
ENTA vs Market: Enanta Pharmaceuticals, Inc. has significantly underperformed the market by -22.18% over the past year.
Stable price: ENTA is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: ENTA with weekly volatility of 0.2702% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (10.94 $) is lower than the fair price (11.59 $).
Price not significantly lower than the fair price: The current price (10.94 $) is slightly lower than the fair price by 5.9%.
4.2. P/E
P/E vs Sector: The company's P/E (436.7) is higher than that of the sector as a whole (48.77).
P/E vs Market: The company's P/E (436.7) is higher than that of the market as a whole (48.3).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (1.07) is lower than that of the sector as a whole (4.82).
P/BV vs Market: The company's P/BV (1.07) is lower than that of the market as a whole (3.18).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (2.94) is lower than that of the sector as a whole (33.76).
P/S vs Market: The company's P/S indicator (2.94) is lower than that of the market as a whole (10.18).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-1.41) is higher than that of the sector as a whole (-22.31).
EV/Ebitda vs Market: The company's EV/Ebitda (-1.41) is lower than that of the market as a whole (18.31).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -77.7% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-77.7%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-9.16%).
5.4. ROE
ROE vs Sector: The company's ROE (-61.74%) is lower than that of the sector as a whole (9.61%).
ROE vs Market: The company's ROE (-61.74%) is lower than that of the market as a whole (10.9%).
5.5. ROA
ROA vs Sector: The company's ROA (-28.95%) is lower than that of the sector as a whole (0.3359%).
ROA vs Market: The company's ROA (-28.95%) is lower than that of the market as a whole (6.48%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (10.79%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5526%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 13.12.2023 | Vance Terry Director |
Sale | 9.12 | 139 490 | 15 295 |
| 05.12.2023 | Luly Jay R. President and CEO |
Sale | 9.63 | 69 625 | 7 230 |
| 05.12.2023 | MELLETT PAUL J Sr. VP, Finance & Admin. & CFO |
Sale | 9.63 | 23 228 | 2 412 |
| 05.12.2023 | Or Yat Sun Sr. VP, R&D & CSO |
Sale | 9.63 | 23 228 | 2 412 |
| 05.12.2023 | Rottinghaus Scott T. Sr. VP & CMO |
Sale | 9.63 | 5 142 | 534 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
